Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

Reck, M; Luft, A; Szczesna, A; Havel, L; Kim, S; Akerley, W; Pietanza, M; Wu, Y; Zielinski, C; Thomas, M; Felip, E; Gold,K; Horn, L; Aerts, J; Nakagawa, K; Lorigan, Paul C; Pieters, A; Kong Sanchez, T; Fairchild, J; Spigel, D

Affiliation

Martin Reck, LungenClinic Grosshansdorf, Airway Research Center North, Grosshansdorf;

Issue Date

2016-07-25

Metadata

Show full item record

Abstract

Patients with extensive-stage disease small-cell lung cancer (SCLC) have poor survival outcomes despite first-line chemotherapy with etoposide and platinum. This randomized, double-blind phase III study evaluated the efficacy and safety of ipilimumab or placebo plus etoposide and platinum in patients with newly diagnosed extensive-stage disease SCLC.

Citation

Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. 2016: J Clin Oncol

Journal

Journal of Clinical Oncology

URI

http://hdl.handle.net/10541/619938

DOI

10.1200/JCO.2016.67.6601

PubMed ID

27458307

Type

Article

Language

ISSN

1527-7755

Collections

All Christie Publications